Patents by Inventor Ramakanth Sarabu

Ramakanth Sarabu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule inhibitors of galectin-3
    Patent number: 11267811
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: March 8, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth Sarabu, Jacob Swidorski, Brett R. Beno, Alicia Regueiro-Ren
  • Febrifugine Derivatives
    Publication number: 20210163443
    Abstract: Disclosed are compounds of Formula I, and pharmaceutically acceptable salts thereof: Also disclosed are pharmaceutical compositions thereof as well as methods for using the compounds in treating a variety of diseases such as, for example, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, ischemic damage, inflammatory diseases, cancers, musculoskeletal diseases, cardiovascular diseases, transplant rejection, multiple sclerosis, systemic sclerosis and neurodegenerative diseases.
    Type: Application
    Filed: December 1, 2020
    Publication date: June 3, 2021
    Inventors: Pravin Sudhakar Shirude, Satheesh Kesavan Nair, Ramesh Kumar Sistla, Ashit K. Ganguly, Ramakanth Sarabu
  • SMALL MOLECULE INHIBITORS OF GALECTIN-3
    Publication number: 20210147408
    Abstract: The present disclosure relates to compounds of formula I, which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: September 27, 2018
    Publication date: May 20, 2021
    Inventors: Prasada Rao Jalagam, Satheesh Kesavan Nair, Manoranjan Panda, Ramakanth SARABU, Jacob SWIDORSKI, Brett R. BENO, Alicia Regueiro-Ren
  • FEBRIFUGINE DERIVATIVES
    Publication number: 20210122746
    Abstract: Disclosed are compounds of Formula (I), and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutically compositions thereof as well as methods for using the compounds in treating a variety of diseases such as, for example, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, ischemic damage, inflammatory diseases, cancers, musculoskeletal diseases, cardiovascular diseases, transplant rejection, multiple sclerosis, systemic sclerosis and neurodegenerative diseases.
    Type: Application
    Filed: December 1, 2018
    Publication date: April 29, 2021
    Inventors: Pravin Shirude, Ashit Ganguly, Ramakanth Sarabu
  • Antiviral compounds
    Patent number: 9180193
    Abstract: The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: November 10, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: John A. Brinkmann, Hongju Li, Ramakanth Sarabu, Sung-Sau So
  • Inhibitors of HCV NS5A
    Patent number: 9133170
    Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Grant
    Filed: December 13, 2012
    Date of Patent: September 15, 2015
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: John A. Brinkman, Ramakanth Sarabu, Sung-Sau So
  • INHIBITORS OF HCV NS5A
    Publication number: 20150166514
    Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: December 13, 2012
    Publication date: June 18, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: John A. Brinkman, Ramakanth Sarabu, Sung-Sau So
  • Antiviral Compounds
    Publication number: 20140255344
    Abstract: The present invention discloses compounds of Formulae I and II, wherein the variables in Formulae I and II are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formulae I and II in the treatment of HCV infection.
    Type: Application
    Filed: October 8, 2012
    Publication date: September 11, 2014
    Applicant: Hiffmann-La Roche Inc.
    Inventors: John A. Brinkmann, Hongju Li, Ramakanth Sarabu, Sung-Sau So
  • ANTIVIRAL COMPOUNDS
    Publication number: 20120328565
    Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the treatment of HCV infection.
    Type: Application
    Filed: June 21, 2012
    Publication date: December 27, 2012
    Inventors: John A. Brinkman, Andrew F. Donnell, Robert Francis Kester, Yimin Qian, Ramakanth Sarabu, Sung-Sau So
  • ANTIVIRAL COMPOUNDS
    Publication number: 20120230951
    Abstract: The present invention provides compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
    Type: Application
    Filed: March 8, 2012
    Publication date: September 13, 2012
    Inventors: Muzaffar Alam, Steven Joseph Berthel, John A. Brinkman, Ronald Charles Hawley, Hongju Li, Wylie Solang Palmer, Sherrie Pietranico-Cole, Ramakanth Sarabu, Mark Smith, Sung-Sau So, Lin Yi, Yansheng Zhai, Qiang Zhang, Shu-Hai Zhao
  • Pyridazinone glucokinase activators
    Patent number: 8258134
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: September 4, 2012
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
  • Tricyclic compounds
    Patent number: 8178689
    Abstract: The present invention provides novel compounds of formula I, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: May 15, 2012
    Assignee: Hoffman-La Roche Inc.
    Inventor: Ramakanth Sarabu
  • TRICYCLIC COMPOUNDS
    Publication number: 20110313002
    Abstract: The present invention provides novel compounds of formula I, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Application
    Filed: June 9, 2011
    Publication date: December 22, 2011
    Inventor: Ramakanth Sarabu
  • Substituted thiazolo[5,4-d]pyrimidine urea derivatives
    Patent number: 7947692
    Abstract: There are presented compounds of the formula or a pharmaceutically acceptable salt thereof, which are active adenosine A2B receptor antagonists and useful in the treatment of diabetes, diabetic retinopathy, asthma and diarrhea.
    Type: Grant
    Filed: May 11, 2007
    Date of Patent: May 24, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: John A. Brinkman, Adrian Wai-Hing Cheung, Fariborz Firooznia, Kevin Richard Guertin, Nicholas Marcopulos, Lida Qi, Jagdish Kumar Racha, Ramakanth Sarabu, Jenny Tan, Jefferson Wright Tilley
  • Pyrazole glucokinase activators
    Patent number: 7935699
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: May 3, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Ramakanth Sarabu, Chinh Viet Tran, Dionisios Vourloumis
  • DPP IV inhibitors
    Patent number: 7803819
    Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, and X are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: September 28, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Markus Boehringer, Daniel Hunziker, Holger Kuehne, Bernd Michael Loeffler, Ramakanth Sarabu, Hans Peter Wessel
  • Pyrrolidinone glucokinase activators
    Patent number: 7741327
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Grant
    Filed: March 9, 2009
    Date of Patent: June 22, 2010
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Steven Joseph Berthel, John A Brinkman, Stuart Hayden, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
  • PYRROLIDINONE GLUCOKINASE ACTIVATORS
    Publication number: 20090264445
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Application
    Filed: March 9, 2009
    Publication date: October 22, 2009
    Inventors: Steven Joseph Berthel, John A. Brinkman, Stuart Hayden, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
  • PYRIDAZINONE GLUCOKINASE ACTIVATORS
    Publication number: 20090264434
    Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.
    Type: Application
    Filed: March 9, 2009
    Publication date: October 22, 2009
    Inventors: Steven Joseph Berthel, Nancy-Ellen Haynes, Robert Francis Kester, Lee Apostle McDermott, Yimin Qian, Ramakanth Sarabu, Nathan Robert Scott, Jefferson Wright Tilley
  • Pyrazole glucokinase activators
    Publication number: 20080021032
    Abstract: Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.
    Type: Application
    Filed: July 19, 2007
    Publication date: January 24, 2008
    Inventors: Steven Joseph Berthel, Robert Francis Kester, Douglas Eric Murphy, Thomas Jay Prins, Frank Ruebsam, Ramakanth Sarabu, Chinh Viet Tran, Dionisios Vourloumis